White Pine Capital LLC Purchases 41,925 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

White Pine Capital LLC increased its position in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 189.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,033 shares of the medical instruments supplier's stock after acquiring an additional 41,925 shares during the quarter. White Pine Capital LLC owned about 0.16% of AngioDynamics worth $587,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Segall Bryant & Hamill LLC grew its position in shares of AngioDynamics by 142.7% in the third quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier's stock valued at $7,091,000 after purchasing an additional 535,958 shares during the last quarter. Systematic Financial Management LP boosted its stake in AngioDynamics by 14.3% during the 3rd quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier's stock valued at $18,752,000 after purchasing an additional 300,785 shares during the period. JPMorgan Chase & Co. grew its holdings in AngioDynamics by 28.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier's stock valued at $4,304,000 after buying an additional 123,271 shares during the last quarter. Royce & Associates LP grew its holdings in AngioDynamics by 10.8% in the 3rd quarter. Royce & Associates LP now owns 986,073 shares of the medical instruments supplier's stock valued at $7,672,000 after buying an additional 96,138 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in AngioDynamics by 110.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 159,391 shares of the medical instruments supplier's stock worth $1,240,000 after buying an additional 83,622 shares during the period. Institutional investors and hedge funds own 89.43% of the company's stock.

Insiders Place Their Bets

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the firm's stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the transaction, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. This trade represents a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.40% of the company's stock.

AngioDynamics Price Performance

Shares of NASDAQ ANGO traded up $0.11 during mid-day trading on Tuesday, hitting $10.45. The company had a trading volume of 465,341 shares, compared to its average volume of 847,366. AngioDynamics, Inc. has a 12 month low of $5.26 and a 12 month high of $13.50. The firm has a market cap of $422.67 million, a P/E ratio of -1.86 and a beta of 0.60. The business's 50-day simple moving average is $10.59 and its 200-day simple moving average is $8.36.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07. The company had revenue of $72.90 million during the quarter, compared to the consensus estimate of $70.93 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company's quarterly revenue was down .1% on a year-over-year basis. During the same quarter last year, the company earned ($0.05) EPS. As a group, sell-side analysts predict that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright increased their price objective on AngioDynamics from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Friday, January 10th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.